休止期脱发与新型冠状病毒感染的相关性及诊疗研究进展

doi:10.35541/cjd.20230069

Abstract

Abstract: 【Abstract】 Telogen effluvium is the most common type of hair loss after coronavirus disease 2019. This review summarizes the literature on associations between coronavirus disease 2019 and telogen effluvium, as well as pathogenesis, diagnosis and treatment of telogen effluvium secondary to coronavirus disease 2019. Sharply increased stress, the body′s immune response, medications, and exacerbation of underlying diseases may be the main precipitating factors for telogen effluvium secondary to coronavirus disease 2019.

Key words: Alopecia, Telogen effluvium, SARS-CoV-2, Stress, psychological

Zhang Shuo, Zhang Wei, Xu Dan. Associations of telogen effluvium with coronavirus disease 2019 and research progress in its diagnosis and treatment[J]. Chinese Journal of Dermatology, 2024, 57(8): 761-764.doi:10.35541/cjd.20230069

References ［43］

［1］	Ocampo⁃Garza SS, Vastarella M, Nappa P, et al. Telogen effluvium in the new SARS⁃CoV⁃2 era［J］. Int J Dermatol, 2021,60（7）:e265⁃e266. doi: 10.1111/ijd.15482.
［2］	Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars⁃Cov⁃2 infection: clinical aspects and our management experience［J］. Dermatol Ther, 2021,34（1）:e14547. doi: 10.1111/dth.14547.
［3］	Sharquie KE, Jabbar RI. COVID⁃19 infection is a major cause of acute telogen effluvium［J］. Ir J Med Sci, 2022,191（4）:1677⁃1681. doi: 10.1007/s11845⁃021⁃02754⁃5.
［4］	Amor K T, Rashid R M, Mirmirani P. Does D matter? The role of vitamin D in hair disorders and hair follicle cycling［J/OL］. Dermatol Online J, 2010,16（2）:3. doi:10.5070/D38s34p6b7.
［5］	Asghar F, Shamim N, Farooque U, et al. Telogen effluvium: a review of the literature［J］. Cureus, 2020,12（5）:e8320. doi: 10.7759/cureus.8320.
［6］	Grover C, Khurana A. Telogen effluvium［J］. Indian J Dermatol Venereol Leprol, 2013,79（5）:591⁃603. doi: 10.4103/0378⁃6323. 116731.
［7］	Olds H, Liu J, Luk K, et al. Telogen effluvium associated with COVID⁃19 infection［J］. Dermatol Ther, 2021,34（2）:e14761. doi: 10.1111/dth.14761.
［8］	Chularojanamontri L, Tuchinda P, Rujitharanawong C, et al. New⁃onset and exacerbated skin diseases after COVID⁃19 infection: a systematic review［J］. J Dermatol, 2022,49（11）:e419⁃e421. doi: 10.1111/1346⁃8138.16501.
［9］	Müller⁃Ramos P, Ianhez M, Silva de Castro CC, et al. Post⁃COVID⁃19 hair loss: prevalence and associated factors among 5 891 patients［J］. Int J Dermatol, 2022,61（5）:e162⁃e164. doi: 10.1111/ijd.16041.
［10］	Cline A, Kazemi A, Moy J, et al. A surge in the incidence of telogen effluvium in minority predominant communities heavily impacted by COVID⁃19［J］. J Am Acad Dermatol, 2021,84（3）:773⁃775. doi: 10.1016/j.jaad.2020.11.032.
［11］	Aksoy H, Yıldırım UM, Ergen P, et al. COVID⁃19 induced telogen effluvium［J］. Dermatol Ther, 2021,34（6）:e15175. doi: 10.1111/dth.15175.
［12］	Tammaro A, Adebanjo G, Parisella FR, et al. Hair and nail manifestations of COVID⁃19［J］. J Cosmet Dermatol, 2022,21（4）:1339⁃1346. doi: 10.1111/jocd.14774.
［13］	Garcovich S, Bersani FS, Chiricozzi A, et al. Mass quarantine measures in the time of COVID⁃19 pandemic: psychosocial implications for chronic skin conditions and a call for qualitative studies［J］. J Eur Acad Dermatol Venereol, 2020,34（7）:e293⁃e294. doi: 10.1111/jdv.16535.
［14］	Rebora A. Telogen effluvium: a comprehensive review［J］. Clin Cosmet Investig Dermatol, 2019,12:583⁃590. doi: 10.2147/CCID.S200471.
［15］	Rivetti N, Barruscotti S. Management of telogen effluvium during the COVID⁃19 emergency: psychological implications［J］. Dermatol Ther, 2020,33（4）:e13648. doi: 10.1111/dth.13648.
［16］	Moreno⁃Arrones OM, Lobato⁃Berezo A, Gomez⁃Zubiaur A, et al. SARS⁃CoV⁃2⁃induced telogen effluvium: a multicentric study［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:e181⁃e183. doi: 10.1111/jdv.17045.
［17］	Headington JT. Telogen effluvium. New concepts and review［J］. Arch Dermatol, 1993,129（3）:356⁃363. doi: 10.1001/archderm. 129.3.356.
［18］	Gentile P. Hair loss and telogen effluvium related to COVID⁃19: the potential implication of adipose⁃derived mesenchymal stem cells and platelet⁃rich plasma as regenerative strategies［J］. International Journal of Molecular Sciences, 2022,23（16）: 9116. doi: 10.3390/ijms23169116.
［19］	Tosti A, Misciali C, Bardazzi F, et al. Telogen effluvium due to recombinant interferon alpha⁃2b［J］. Dermatology, 1992,184（2）:124⁃125. doi: 10.1159/000247518.
［20］	Rossi A, Magri F, Sernicola A, et al. Telogen effluvium after SARS⁃CoV⁃2 infection: a series of cases and possible pathogenetic mechanisms［J］. Skin Appendage Disord, 2021,21（5）:1⁃5. doi: 10.1159/000517223.
［21］	Hussain N, Agarwala P, Iqbal K, et al. A systematic review of acute telogen effluvium, a harrowing post⁃COVID⁃19 manifestation［J］. J Med Virol, 2022,94（4）:1391⁃1401. doi: 10. 1002/jmv.27534.
［22］	Kato H, Kinoshita K, Saito N, et al. The effects of ischemia and hyperoxygenation on hair growth and cycle［J］. Organogenesis, 2020,16（3）:83⁃94. doi: 10.1080/15476278.2020.1794271.
［23］	Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID⁃19 acute respiratory distress syndrome［J］. J Thromb Haemost, 2020,18（7）:1747⁃1751. doi: 10.1111/jth.14854.
［24］	Connors JM, Levy JH. COVID⁃19 and its implications for thrombosis and anticoagulation［J］. Blood, 2020,135（23）:2033⁃2040. doi: 10.1182/blood.2020006000.
［25］	Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID⁃19 and cardiovascular disease［J］. Circulation, 2020,141（20）:1648⁃1655. doi: 10.1161/CIRCULATIONAHA.120.046941.
［26］	Almeida G, Arruda S, Marques E, et al. Presentation and management of cutaneous manifestations of COVID⁃19［J］. J Drugs Dermatol, 2021,20（1）:76⁃83. doi: 10.36849/JDD.5676.
［27］	Bongiovanni M, Chiesa E, Monforte Ad, et al. Hair loss in an HIV⁃1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART［J/OL］. Dermatol Online J, 2003,9（5）:28.
［28］	Watras MM, Patel JP, Arya R. Traditional anticoagulants and hair loss: a role for direct oral anticoagulants? A review of the literature［J］. Drugs Real World Outcomes, 2016,3（1）:1⁃6. doi: 10.1007/s40801⁃015⁃0056⁃z.
［29］	Borrás⁃Blasco J, Belda A, Rosique⁃Robles D, et al. Hair loss induced by lopinavir⁃ritonavir［J］. Pharmacotherapy, 2007,27（8）:1215⁃1218. doi: 10.1592/phco.27.8.1215.
［30］	Cline A, Jacobs AK, Fonseca M, et al. Race, ethnicity, and comorbidities are critical factors in the diagnosis of telogen effluvium during the COVID⁃19 pandemic［J］. J Am Acad Dermatol, 2021,85（1）:209⁃211. doi: 10.1016/j.jaad.2021.03.099.
［31］	Cheung EJ, Sink JR, English Iii JC. Vitamin and mineral deficiencies in patients with telogen effluvium: a retrospective cross⁃sectional study［J］. J Drugs Dermatol, 2016,15（10）:1235⁃1237.
［32］	Lee Y, Min P, Lee S, et al. Prevalence and duration of acute loss of smell or taste in COVID⁃19 patients［J］. J Korean Med Sci, 2020,35（18）:e174. doi: 10.3346/jkms.2020.35.e174.
［33］	Duntas LH, Jonklaas J. COVID⁃19 and thyroid diseases: a bidirectional impact［J］. J Endocr Soc, 2021,5（8）:bvab076. doi: 10.1210/jendso/bvab076.
［34］	Baldelli R, Nicastri E, Petrosillo N, et al. Thyroid dysfunction in COVID⁃19 patients［J］. J Endocrinol Invest, 2021,44（12）:2735⁃2739. doi: 10.1007/s40618⁃021⁃01599⁃0.
［35］	Lause M, Kamboj A, Fernandez Faith E. Dermatologic manifestations of endocrine disorders［J］. Transl Pediatr, 2017,6（4）:300⁃312. doi: 10.21037/tp.2017.09.08.
［36］	Alessandrini A, Bruni F, Piraccini BM, et al. Common causes of hair loss ⁃ clinical manifestations, trichoscopy and therapy［J］. J Eur Acad Dermatol Venereol, 2021,35（3）:629⁃640. doi: 10.1111/ jdv.17079.
［37］	Abrantes TF, Artounian KA, Falsey R, et al. Time of onset and duration of post⁃COVID⁃19 acute telogen effluvium［J］. J Am Acad Dermatol, 2021,85（4）:975⁃976. doi: 10.1016/j.jaad.2021. 07.021.
［38］	Trüeb RM, Dutra Rezende H, Gavazzoni Dias M. What can the hair tell us about COVID⁃19?［J］. Exp Dermatol, 2021,30（2）:288⁃290. doi: 10.1111/exd.14259.
［39］	Miteva M, Tosti A. Hair and scalp dermatoscopy［J］. J Am Acad Dermatol, 2012,67（5）:1040⁃1048. doi: 10.1016/j.jaad.2012.02. 013.
［40］	Nguyen B, Tosti A. Alopecia in patients with COVID⁃19: a systematic review and meta⁃analysis［J］. JAAD Int, 2022,7:67⁃77. doi: 10.1016/j.jdin.2022.02.006.
［41］	Bertoli MJ, Sadoughifar R, Schwartz RA, et al. Female pattern hair loss: a comprehensive review［J］. Dermatol Ther, 2020,33（6）:e14055. doi: 10.1111/dth.14055.
［42］	Popescu MN, Berteanu M, Beiu C, et al. Complementary strategies to promote hair regrowth in post⁃COVID⁃19 telogen effluvium［J］. Clin Cosmet Investig Dermatol, 2022,15:735⁃743. doi: 10.2147/CCID.S359052.
［43］	İşlek A, Karaaslan E, Şimşek S, et al. Platelet⁃rich plasma treatment for accelerated androgenetic alopecia pattern hair loss after COVID⁃19 infection: a case series［J］. J Cosmet Dermatol, 2022,21（2）:590⁃594. doi: 10.1111/jocd.14721.

[1]	Tao Qiuwei, Chen Qitao, Shao Guanghui, Li Yuqian, Zhu Qilin, Zhu Jing, Li Zhongming, Du Xufeng. Morphea alopecia [J]. Chinese Journal of Dermatology, 2024, 0(3): 20220829-e20220829.
[2]	Wei Ran, Li Qinfeng. Novel targeted drugs for the treatment of pediatric alopecia areata [J]. Chinese Journal of Dermatology, 2024, 0(3): 20230660-e20230660.
[3]	Wang Yuting, Yao Manxue, Zhou Naihui. Combined microneedling for the treatment of androgenetic alopecia [J]. Chinese Journal of Dermatology, 2024, 57(1): 82-84.
[4]	Liu Yuanxiang, Liang Yuan, Zhao Xinrong, Sun Yujuan, Ma Lin, Xu Zigang. Janus kinase inhibitors for the treatment of five children with severe alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 849-852.
[5]	Sun Xiaojie, Liu Yi. Anti-androgen drugs in the treatment of skin diseases [J]. Chinese Journal of Dermatology, 2023, 56(9): 882-885.
[6]	Wang Yuqian, Qiao Jianjun, Fang Hong. Comparison of the latest Chinese and international guidelines/consensus on diagnosis and treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2023, 56(9): 885-888.
[7]	Zhang Li, Song Xiuzu. Role of vascular endothelial growth factor in androgenetic alopecia [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220240-e20220240.
[8]	Shao Guanghui, Li Yuqian, Chen Qitao, Zhu Qilin, Zhu Jing, Li Zhongming, Du Xufeng, Fan Weixin. Congenital triangular alopecia [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220301-e20220301.
[9]	Sha Yuou, Wei Kelu, Lin Jinran, Liu Qingmei, Ni Chunya, Wu Wenyu, . Fibrosing alopecia in a pattern distribution [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220014-e20220014.
[10]	Shen Yuqing, Song Xiuzu. Ultraviolet and androgenetic alopecia [J]. Chinese Journal of Dermatology, 2023, 0(2): 20210949-e20210949.
[11]	Sun Jiayi, Song Xiuzu. Autophagy in hair physiology and pathology [J]. Chinese Journal of Dermatology, 2023, 0(2): 20220036-e20220036.
[12]	Deng Wei, Zhang Gaolei, Chen Jianyou, Zhang Sheng, Jiang Lixiao, Liu Xiaoyan, Su Wei. Skin manifestations of 61 children with coronavirus disease 19 [J]. Chinese Journal of Dermatology, 2023, 56(12): 1154-1157.
[13]	Li Yuqian, Zhu Qilin, Zhu Jing, Chen Qitao, Li Zhongming, Xu Wenrong, Du Xufeng, Fan Weixin. Frontal fibrosing alopecia [J]. Chinese Journal of Dermatology, 2023, 56(10): 973-977.
[14]	Zhao Peng, Qin Xiaowei, Qin Junxia, Liang Lili, Zhang Xinzhong, Gao Jie. Regulatory effect of interleukin-18 on natural killer cell activity in patients with alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(9): 778-783.
[15]	Ding Yuxin, Lyu Zhongfa. Stem cell therapy for alopecia areata [J]. Chinese Journal of Dermatology, 2022, 55(9): 835-838.

Associations of telogen effluvium with coronavirus disease 2019 and research progress in its diagnosis and treatment

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［43］

Related Articles 15

Metrics

Comments

Recommended 10